• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.

作者信息

Schmierer Klaus, Wiendl Heinz, Oreja-Guevara Celia, Centonze Diego, Chudecka Anita, Roy Sanjeev, Boschert Ursula

机构信息

Centre for Neuroscience, Surgery & Trauma, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.

出版信息

Mult Scler. 2022 Nov;28(13):2151-2153. doi: 10.1177/13524585221099413. Epub 2022 Jun 7.

DOI:10.1177/13524585221099413
PMID:35672923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9574232/
Abstract
摘要

相似文献

1
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.来自MAGNIFY-MS研究中接受克拉屈滨片治疗的高度活动性复发型多发性硬化症患者的水痘带状疱疹病毒和流感疫苗抗体滴度。
Mult Scler. 2022 Nov;28(13):2151-2153. doi: 10.1177/13524585221099413. Epub 2022 Jun 7.
2
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.关于用克拉屈滨片剂治疗多发性硬化症的人群中接种流感疫苗和水痘疫苗的影响的通俗语言摘要。
Neurodegener Dis Manag. 2023 Feb;13(1):15-21. doi: 10.2217/nmt-2022-0026. Epub 2022 Dec 22.
3
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.克拉屈滨片治疗波兰活跃复发缓解型多发性硬化症的真实世界、多中心、回顾性队列研究：COVID-19 大流行期间。
Neurol Neurochir Pol. 2023;57(4):371-378. doi: 10.5603/PJNNS.a2023.0050. Epub 2023 Jul 25.
4
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.复发缓解型多发性硬化症中克拉屈滨治疗的真实世界经验：一项丹麦全国性研究。
Mult Scler Relat Disord. 2023 Feb;70:104491. doi: 10.1016/j.msard.2022.104491. Epub 2022 Dec 28.
5
[Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].[使用克拉屈滨（片剂）治疗缓解型多发性硬化症成年患者的药物经济学方面]
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(8):30-36. doi: 10.17116/jnevro202112108130.
6
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.CLICK-MS 和 MASTER-2 四期临床试验设计：克拉屈滨片治疗控制不佳的复发型多发性硬化症。
Neurodegener Dis Manag. 2021 Apr;11(2):99-111. doi: 10.2217/nmt-2020-0059. Epub 2021 Feb 1.
7
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].[关于GLIMPSE研究的评论：评估片剂形式的克拉屈滨药物在常规临床实践中与其他用于多发性硬化症病因治疗的片剂药物相比的疗效]
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):73-77. doi: 10.17116/jnevro202212207273.
8
Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.在英国，多发性硬化症患者使用克拉屈滨片的真实世界应用（完成率和治疗持久性）：CLARENCE 研究。
Mult Scler Relat Disord. 2023 Nov;79:104951. doi: 10.1016/j.msard.2023.104951. Epub 2023 Aug 21.
9
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.关于评估克拉屈滨片对复发型多发性硬化症患者长期疗效的简明语言总结：CLASSIC-MS研究。
Neurodegener Dis Manag. 2023 Oct;13(5):261-268. doi: 10.2217/nmt-2023-0018. Epub 2023 Aug 3.
10
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.在葡萄牙，克拉屈滨片与芬戈莫德治疗高度活跃复发型多发性硬化症的成本效益比较。
J Med Econ. 2020 May;23(5):484-491. doi: 10.1080/13696998.2020.1717499. Epub 2020 Feb 10.

引用本文的文献

1
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.克拉屈滨治疗复发型多发性硬化症的临床及机制效应：MAGNIFY-MS研究的2年结果
Ther Adv Neurol Disord. 2025 Jul 31;18:17562864251351760. doi: 10.1177/17562864251351760. eCollection 2025.
2
Cladribine tablets in the new multiple sclerosis era.新多发性硬化症时代的克拉屈滨片
Ther Adv Neurol Disord. 2025 Jun 19;18:17562864251342855. doi: 10.1177/17562864251342855. eCollection 2025.
3
Tetanus and Diphtheria Toxoid-Containing Vaccine in Multiple Sclerosis Patients: A Real-World Prospective, Open-Label, Multi-Centre Study.破伤风和白喉类毒素疫苗在多发性硬化症患者中的应用：一项真实世界的前瞻性、开放标签、多中心研究。
Vaccines (Basel). 2025 Apr 24;13(5):451. doi: 10.3390/vaccines13050451.
4
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.高效多发性硬化症疗法对B细胞的影响。
Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606.
5
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.用克拉屈滨片治疗复发型多发性硬化症患者的血液生物标志物动态变化：为期2年的MAGNIFY-MS研究结果
Front Immunol. 2025 Feb 3;16:1512189. doi: 10.3389/fimmu.2025.1512189. eCollection 2025.
6
Effects of cladribine on intrathecal and peripheral B and plasma cells.克拉屈滨对鞘内及外周B细胞和浆细胞的作用。
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae116.
7
Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals.让多发性硬化症患者能够获取有关克拉屈滨片的信息：一项以患者调查为导向的医疗专业人员叙述性综述
Neurol Ther. 2024 Aug;13(4):1015-1038. doi: 10.1007/s40120-024-00608-7. Epub 2024 May 17.
8
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.ECTRIMS/EAN 关于多发性硬化症患者接种疫苗的共识：在高度活跃的免疫治疗药物时代改进免疫策略。
Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9.
9
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine.多发性硬化症患者接受克拉屈滨治疗时对季节性流感疫苗的免疫应答。
Cells. 2023 Apr 25;12(9):1243. doi: 10.3390/cells12091243.
10
Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients.克拉屈滨治疗可特异性影响多发性硬化症患者外周血记忆 B 细胞克隆及其克隆性扩张。
Front Immunol. 2023 Mar 7;14:1133967. doi: 10.3389/fimmu.2023.1133967. eCollection 2023.

本文引用的文献

1
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.奥瑞珠单抗、阿仑单抗和克拉屈滨治疗后 CD19 B 细胞重建：对多发性硬化症中 SARS-CoV-2 疫苗接种的影响。
Mult Scler Relat Disord. 2022 Jan;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 4.
2
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.SARS-CoV-2 mRNA 疫苗接种对接受疾病修正治疗的 MS 患者的影响。
EBioMedicine. 2021 Oct;72:103581. doi: 10.1016/j.ebiom.2021.103581. Epub 2021 Sep 22.
3
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.接受高效疾病修正治疗的多发性硬化症患者对新冠病毒mRNA疫苗的体液免疫反应
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021.
4
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.芬戈莫德治疗的多发性硬化症患者疫苗接种的随机试验。
Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30.